The consensus marks a sequential improvement from the third quarter, when Amneal earned $0.17 per share on revenue of $785 million. Investors will scrutinize whether the Bridgewater, N.J.-based ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.
The editorial board is a group of opinion journalists whose views are informed by expertise, research, debate and certain longstanding values. It is separate from the newsroom. The federal government ...
Amneal Pharmaceuticals re c eived FDA approval for two denosumab biosimilars referencing Prolia and Xgeva. The approval, announced Dec. 22, covers Boncresa (denosumab-mobz) and Oziltus (denosumab-mobz ...
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership ...
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced ...
Amneal Pharmaceuticals and mAbxience received Food and Drug Administration approval for two biosimilars. The companies said Monday that the FDA greenlit Biologics Licensing Applications for Boncresa, ...
The Trump administration will appeal a federal judge’s ruling that declared the rescission of $2.6 billion in federal funds from Harvard University was unconstitutional. U.S. District Judge Allison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results